Christina Weng
Ophthalmology · Houston, TXNPI 1073789061
Payments from drug & device makers
Across 554 payments — averaging $1302.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$213K
- Alcon$113K
- Alimera Sciences, Inc.$69K
- Alcon Research LLC$41K
- Spark Therapeutics, Inc.$35K
- Novartis$33K
- plus $218K from 26 others
Across 13 payments — averaging $2608.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alimera Sciences, Inc.$23K
- F. Hoffmann-la Roche AG$10K
- AbbVie$775
What the payments were for
- Consulting fees$540,69280%
- Speaking & faculty fees$93,99014%
- Travel & lodging$23,7634%
- Food & beverage$14,2602%
- Other$2,8520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$129,166
- Iluvien$71,775
- Constellation$67,304
- BEOVU$31,612
- EYLEA$23,832
- EYP-1901$16,663
- VABYSMO$15,543
- Izervay$14,140
- EYLEA HD$13,156
- EVA Ophthalmic Surgical System$12,550
- AcrySof$12,469
- YUTIQ$12,270
- CIRRUS HD-OCT$10,329
- Lucentis$9,140
- Syfovre$7,585
- CLARUS$7,125
- ILUX$7,000
- Systane$7,000
- Hydrus Microstent$7,000
- LenSx$7,000
How this compares
$721,625 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 47 | $1,982 |
| Ketorolac Tromethamine | 36 | $1,667 |
| Tobramycin | 13 | $44 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Houston
- David BrownHouston$51.7M
- John MichelettiHouston$3.3M
- Michael CaplanHouston$1.4M
- Shaheen KavoussiHouston$1.3M
- Kevin JongHouston$1.2M
- Stephen SladeHouston$1.2M
- Rosa TangHouston$1.1M
- Zaina Al-MohtasebHouston$1.1M
- Fiaz ZamanHouston$1M
- Stephen PflugfelderHouston$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.